Japan's Dainippon Sees Success In Phase III Trials For Schizophrenia Drug
This article was originally published in PharmAsia News
Executive Summary
Dainippon Sumitomo Pharma of Japan reported Phase III success with its lurasidone drug to treat schizophrenia. The company said that as a result, it plans to apply to the U.S. FDA early next year for approval. The drug is part of the atypical antipsychotics class of drug that works by blocking brain serotonin receptors. The final-stage trial was conducted on patients who had schizophrenia for an average of 13 years and had been hospitalized recently. (Click here for more